Gossamer Bio (GOSS) vs Medicinova (MNOV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Medicinova (MNOV) has outperformed Gossamer Bio (GOSS) over the past year, losing 8.4% versus a loss of 95.6%. Over five years, MNOV leads with a -59.3% price change compared with -98.7% for GOSS. Medicinova is the larger company by market cap ($67.1 million vs $65.6 million), about 1.0 times the size.
Gossamer Bio converts more of its revenue into profit, with a net margin of -351.5% versus -2928.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GOSS | MNOV |
|---|---|---|
| Share price | $10.72 | $1.31 |
| Market cap | $65.57M | $67.11M |
| 1-day change | -4.54% | +3.15% |
| YTD return | -95.68% | 0.00% |
| 1-year return | -95.62% | -8.39% |
| 5-year return | -98.74% | -59.32% |
| EPS (TTM) | $-42.41 | $-0.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $48.47M | $409.66K |
| Revenue growth (YoY) | -57.74% | — |
| Net income (latest FY) | $-170.37M | $-12.00M |
| Operating margin | -352.23% | -3242.47% |
| Net margin | -351.49% | -2928.78% |
| 52-week high | $309.60 | $3.90 |
| 52-week low | $8.29 | $1.22 |
| Distance from 52-week high | -96.54% | -66.41% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +669.40% | +529.77% |
| Average volume | 243.40K | 334.96K |
| Shares outstanding | 6.12M | 51.23M |
| Employees | 161 | 6 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MNOV has outperformed GOSS by 87.2 percentage points over the past year.
- Gossamer Bio is more profitable, keeping -351.5 cents of every revenue dollar as net income versus -2928.8 cents for Medicinova.
About Gossamer Bio
GOSS stock →Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.
Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees
About Medicinova
MNOV stock →MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
GOSS vs MNOV FAQ
Which is bigger, Gossamer Bio or Medicinova?
Medicinova (MNOV) is larger, with a market capitalization of $67.11M compared with $65.57M for Gossamer Bio (GOSS).
Which stock has performed better over the past year, GOSS or MNOV?
MNOV returned -8.39% over the past 12 months, compared with -95.62% for GOSS (price return, excluding dividends). Past performance does not predict future results.
Are Gossamer Bio and Medicinova in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.